NEW YORK--(BUSINESS WIRE)--OMRIX Biopharmaceuticals, Inc. (“OMRIX” or the “Company”)(NASDAQ: OMRI), a commercial-stage biopharmaceutical company that develops and markets biosurgical and antibody-based products, will announce financial results for the third quarter ended September 30, 2006 before the open of U.S. financial markets on Tuesday, November 7, 2006. An accompanying conference call to discuss the results will be held the same day at 10:00 a.m. ET; 7:00 a.m. PT.
